ScholarIQanswers from OpenAlex & ORCID
John Bridgewater
ResearcherPublications, citations & collaboration network
John Bridgewater is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does John Bridgewater have?
ScholarIQindexed works
John Bridgewater has 452 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does John Bridgewater have?
ScholarIQcitation count
John Bridgewater has 36,977 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of John Bridgewater?
ScholarIQh-index
John Bridgewater has an h-index of 67 in OpenAlex.
What is the i10-index of John Bridgewater?
ScholarIQi10-index
John Bridgewater has an i10-index of 192 in OpenAlex.
What is the ORCID of John Bridgewater?
ScholarIQorcid
The ORCID for John Bridgewater is on the source record.
What is the OpenAlex record for John Bridgewater?
ScholarIQopenalex
The OpenAlex for John Bridgewater is on the source record.
What are the most-cited papers on John Bridgewater?
ScholarIQmost cited works
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesús M. Bañales, José J.G. Marı́n, Ángela Lamarca, Pedro M. Rodrigues, Shahid A. Khan, Lewis R. Roberts, Vincenzo Cardinale, Guido Carpino, Jesper B. Andersen, Chiara Braconi, Diego F. Calvisi, María J. Perugorria, Luca Fabris, Luke Boulter, Rocı́o I.R. Macı́as, Eugenio Gaudio, Domenico Alvaro, Sergio A. Gradilone, Mario Strazzabosco, Marco Marzioni, Cédric Coulouarn, Laura Fouassier, Chiara Raggi, Pietro Invernizzi, Joachim C. Mertens, Anja Moncsek, Sumera I. Ilyas, Julie K. Heimbach, Bas Groot Koerkamp, Jordi Bruix, Alejandro Forner, John Bridgewater, Juan W. Valle, Gregory J. Gores
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan, Paul J. Ross, Yuk Ting, Arvind Arora, Stephen Falk, Roopinder Gillmore, Jonathan Wadsley, Kinnari Patel, Alan Anthoney, Anthony Maraveyas, Timothy Iveson, Justin S. Waters, Claire Hobbs, Safia Barber, W. David J. Ryder, John Ramage, Linda Davies, John Bridgewater, Juan W. Valle
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Arndt Vogel, John Bridgewater, Julien Edeline, Robin Kate Kelley, Heinz‐Josef Klümpen, David Malka, John Primrose, Lorenza Rimassa, Albrecht Stenzinger, Juan W. Valle, Michel Ducreux
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Yuichiro� Doki, Jaffer A. Ajani, Ken Kato, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih‐Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Sandra A. Ostoich, Hye R. Kim, Masaki Ueno, Wasat Mansoor, Wen‐Chi Yang, Tianshu Liu, John Bridgewater, Tomoki Makino, Ioannis Xynos, Xuan Liu, Ming Lei, Kaoru Kondo, Apurva Patel, Joseph Gricar, Ian Chau, Yuko Kitagawa, Doki, Yuichiro, Jaffer A. Ajani, Ken Kato, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Hsu, Chih Hung, Antoine Adenis, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Sandra A. Ostoich, Hye R. Kim, Masaki Ueno, Wasat Mansoor, Yang, Wen Chi, Tianshu Liu, John Bridgewater, Tomoki Makino, Ioannis Xynos, Xuan Liu, Ming Lei, Kaoru Kondo, Apurva Patel, Joseph Gricar, Ian Chau, Yuko Kitagawa
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
Julien Taı̈eb, Josep Tabernero, Enrico Mini, Fabien Subtil, Gunnar Folprecht, Jean-Luc Van Laethem, J. Thaler, John Bridgewater, Lone Nørgård Pétersen, Hélène Blons, Laurence Collette, Eric Van Cutsem, Philippe Rougier, Ramón Salazar, Laurent Bedenne, Jean‐François Emile, Pierre Laurent‐Puig, Côme Lepage